Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271512 · ClinicalTrials.gov registry record
A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
A clinical trial of Beta-Thalassemia, sponsored by Genetix Biotherapeutics.
- Recruiting
- Registry status
- 150
- Enrollment target
- 6
- Study locations
NCT06271512 is a study of Beta-Thalassemia that is actively recruiting participants, run by Genetix Biotherapeutics. The registered enrollment target is 150 participants, below the 170-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (12% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06271512, a study of Beta-Thalassemia, is actively recruiting participants, sponsored by Genetix Biotherapeutics.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel and evaluate the long-term effectiveness of treatment with beti-cel.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (6)
California
- UCSF Benioff Children's Hospitals - Oakland
- Stanford University - Palo Alto
Minnesota
- University of Minnesota - Minneapolis
New York
- Cohen Children's Medical Center - New Hyde Park
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2043-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06271512
The ClinicalTrials.gov registry entry for NCT06271512 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 14 other Beta-Thalassemia trials with a reported enrollment target (12% lower). The listed sponsor is Genetix Biotherapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Beta-Thalassemia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT06271512 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Minnesota, New York.
Frequently Asked Questions
What is clinical trial NCT06271512 about?
NCT06271512 is a clinical study titled "A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel". The main aim of this study is to collect real-world longitudinal data on participants with β-thalassemia treated with betibeglogene autotemcel (beti-cel) in the post marketing setting. To assess the long-term safety, including the risk of newly diagnosed malignancies, after treatment with beti-cel a...
What is the current status of trial NCT06271512?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-01-23. Estimated completion is 2043-12.
What conditions does trial NCT06271512 study?
This clinical trial studies the following conditions: Beta-Thalassemia.
What interventions are being tested in trial NCT06271512?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT06271512?
This trial is sponsored by Genetix Biotherapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271512 being conducted?
This trial has 6 study locations across California, Minnesota, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Beta-Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
RECRUITING
-
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
RECRUITING · Phase 2
-
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
RECRUITING · Phase 1
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.